AstraZeneca's Rezield Might Itself Be Saved By Sicker Patients

Members of FDA's Antiviral Drugs Advisory Committee say that MedImmune's RSV drug Rezield (motavizumab) doesn't pass the risk-benefit test for healthier patients, but it might for sicker patients.